HOME >> MEDICINE >> NEWS
EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Porter Novelli
27-Mar-2007


Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... 31, 2020 , ... Dr. Chang has over 20 years ... other developmental disabilities, as well as supporting staff in caring for patients and ... consultation, and staff development. She joined the company in 2015 as Chief of ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst ... Mandeville was named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now ... leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free ... to continue helping the specialty-diet community connect with great, gluten-free brands. At the ... enter giveaways, chat with brands & watch over 50 educational classes... all online ...
(Date:8/28/2020)... LOS ANGELES (PRWEB) , ... August 28, 2020 ... ... reports on international observations that strongly suggest that obese individuals are at an ... obese people are any more likely to catch COVID-19; however, because the same ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... Evolution Labs to provide their students with Suite360:Mental Health and Prevention, a program ... Substance Abuse and Child Trafficking Prevention. , Florida schools and districts must provide ...
Breaking Medicine News(10 mins):
(Date:8/28/2020)... ... , ... Dr. Mark Surrey has been in practice for over 25 ... professor in the Department of OBGYN at UCLA’s David Geffen School of Medicine. ... Society and is a Clinical Director of Fellowship Training for UCLA & Cedars Sinai ...
(Date:8/27/2020)... ... August 27, 2020 , ... Austin Oral Surgery – ... pleased to announce Dr. David Szalay, DDS, MD, has joined the practice. An accomplished ... the new Pflugerville office, which is scheduled to open this fall. The new office ...
(Date:8/27/2020)... , ... August 27, 2020 , ... ... has partnered with Enquire, a leading provider of cloud CRM, marketing automation, and ... organizations' strategic partnership will involve the integration of Trella’s performance intelligence data and ...
Breaking Medicine Technology:
Cached News: